It belongs to the sodium-glucose cotransporter 2 (SGLT2) inhibitor group [2,3,4]—medications introduced for the treatment of the type 2 diabetes mellitus (T2DM). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.